Elafibranor

产品说明书

Print
Chemical Structure| 923978-27-2 同义名 : -
CAS号 : 923978-27-2
货号 : A118286
分子式 : C22H24O4S
纯度 : 95%
分子量 : 384.489
MDL号 : MFCD27987940
存储条件:

Pure form Sealed in dry,2-8°C

In solvent -20°C:3-6个月-80°C:12个月

溶解度 :

DMSO: 35 mg/mL(91.03 mM),注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

动物实验配方:
生物活性
描述 Elafibranor, also known as GFT505, is a dual agonist of peroxisome proliferator-activated receptor-α/δ (PPAR-α/δ) with EC50 values of 45 and 175nM, respectively[3]. Treatment of hApoE2 KI mice with Elafibranor (30 mg/kg/day) for 6 weeks significantly decreased the plasma concentrations of total cholesterol, triglycerides, and free fatty acids, and greatly increased the level of high-density lipoprotein cholesterol compared to vehicle-treated group. In both hApoE2 KI and hApoE2 KI/PPAR‐α KO mice, Elafibranor treatment significantly reduced hepatic expressions of interleukin‐1β, tumor necrosis factor‐α, transforming growth factor‐β, and tissue inhibitor of metalloproteinase-2. Methionine- and choline-deficient diet induced steatohepatitis in db/db mice, whereas supplementation with Elafibranor (1, 3, or 10 mg/kg/day) for 7 weeks reduced intrahepatic cholesterol and triglyceride content in a dose‐dependent manner. In SD rats concomitantly injected with CCl4 and treated with Elafibranor (30 mg/kg/day) for 7 weeks, the fibrotic surface and hepatic collagen content were significantly decreased, and the number of macrophages and activated hepatic stellate cells were significantly reduced as compared to CCl4 control group[4].
作用机制 Elafibranor is a PPAR-α/δ agonist that exhibits liver-protective effects in non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and liver fibrosis. It has also been shown to reduce fasting glucose and improve insulin sensitivity similar to PPAR-γ agonist rosiglitazone.
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

2.60mL

0.52mL

0.26mL

13.00mL

2.60mL

1.30mL

26.01mL

5.20mL

2.60mL

参考文献

[1]Ratziu V, Harrison SA, et al. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. Gastroenterology. 2016 May;150(5):1147-1159.e5.

[2]Liu ZM, Hu M, et al. Early investigational drugs targeting PPAR-α for the treatment of metabolic disease. Expert Opin Investig Drugs. 2015 May;24(5):611-21.

[3]Liu ZM, Hu M, Chan P, Tomlinson B. Early investigational drugs targeting PPAR-α for the treatment of metabolic disease. Expert Opin Investig Drugs. 2015 May;24(5):611-21. doi: 10.1517/13543784.2015.1006359. Epub 2015 Jan 21. PMID: 25604802.

[4]Staels B, Rubenstrunk A, Noel B, Rigou G, Delataille P, Millatt LJ, Baron M, Lucas A, Tailleux A, Hum DW, Ratziu V, Cariou B, Hanf R. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology. 2013 Dec;58(6):1941-52. doi: 10.1002/hep.26461. Epub 2013 Oct 29. PMID: 23703580.